Stroke prevention in Atrial Fibrillation

Abstract

Stroke prevention is the cornerstone of the management of atrial fibrillation (AF), and effective stroke prevention means oral anticoagulation (OAC), irrespective of symptoms or whether a rate or rhythm control approach is employed.1 Whilst the Vitamin K antagonists (VKA, e.g. warfarin) remains widely used worldwide, the landscape of stroke prevention has changed markedly in recent years, with the availability of the non-Vitamin K antagonist oral anticoagulants, the novel oral anticoagulants (NOACs), with increasing ‘real world’ data supporting their use in everyday clinical practice.2–4

Read More

Citation
Eur Heart J. 2017 Jan 1;38(1):4-5.